Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Several endocrine therapies are currently available for the treatment of estrogen receptor (ER) positive breast cancer, but the clinical benefit of these agents is limited by endocrine therapy drug resistance. A common mechanism of endocrine therapy resistance is ESR1 mutations. The first-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Downton, Teesha, Zhou, Fiona, Segara, Davendra, Jeselsohn, Rinath, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447452/
https://www.ncbi.nlm.nih.gov/pubmed/36081610
http://dx.doi.org/10.2147/DDDT.S380925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447452/
https://www.ncbi.nlm.nih.gov/pubmed/36081610
http://dx.doi.org/10.2147/DDDT.S380925

Ejemplares similares